单位:[1]Peking University People’s Hospital, Beijing, China[2]ShanghaiJiaotong University Ruijin Hospital, Shanghai, China[3]NanfangHospital of Southern Medical University, Guangzhou,China[4]West China Hospital, Sichuan University, Chengdu,China四川大学华西医院[5]Tongji Hospital of Tongji Medical College, HuanzhongUniversity of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[6]BeijingDitan Hospital Affiliated to Capital Medical University, Beijing,China[7]The Third Hospital of Hebei Medical University, Hebei,China[8]The First Affiliated Hospital of Nanchang University,Nanchang, China[9]The First Affiliated Hospital with NanjingMedical University, Nanjing, China[10]The First Affiliated Hospitalof Guangxi Medical University, Guangxi, China[11]ClinicalResearch, Gilead Sciences Inc, Foster City, CA[12]Biostatistics,Gilead Sciences, Inc, Foster City, CA[13]Virology, Gilead Sciences,Inc, Foster City, CA[14]The Second Xiangya Hospital ofCentral South University, Changsha, China[15]Jinan InfectiousDisease Hospital, Jinan, China[16]Clinical Center of ShanghaiPublic Health, Shanghai, Shanghai, China[17]Peking UniversityFirst Hospital, Beijing, China[18]The Second Affiliated Hospitalof Chongqing Medical University, Chongqing, China[19]TheFirst Hospital of Jilin University, Changchun, China[20]BeijingFriendship Hospital affiliated to Capital Medical University,Beijing, China首都医科大学附属北京友谊医院[21]Beijing Youan Hospital Affiliated to CapitalMedical University, Beijing, China
第一作者单位:[1]Peking University People’s Hospital, Beijing, China
推荐引用方式(GB/T 7714):
Lai Wei,Qing Xie,Jinlin Hou,et al.Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population: Results from a Phase 3, Clinical Trial[J].HEPATOLOGY.2017,66:642A-642A.
APA:
Lai Wei,Qing Xie,Jinlin Hou,Hong Tang,Qin Ning...&Zhongping Duan.(2017).Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population: Results from a Phase 3, Clinical Trial.HEPATOLOGY,66,
MLA:
Lai Wei,et al."Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population: Results from a Phase 3, Clinical Trial".HEPATOLOGY 66.(2017):642A-642A